President Donald Trump signed an executive order to increase federal research into psychedelic drugs, with a specific focus on ibogaine as a potential treatment for post-traumatic stress disorder and traumatic brain injuries. The White House will allocate $50 million for terminally ill patients to access ibogaine under the Right to Try law, though these substances will remain Schedule I illegal outside clinical settings.
Administration officials view these drugs as potential alternatives to current antidepressants, citing their promise for severe mental illness and depression, particularly among veterans. “In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans,” Trump said. “Our veterans are having a tremendous hard time. You know, the suicide rate—we have it down a little bit—but they are having a hard time.”
Early research, including a Stanford study, suggests ibogaine can be effective with magnesium and has shown dramatic results for traumatic brain injury symptoms. The small study of 30 participants reported no serious side effects. Study author Nolan Williams said: “No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury. The results are dramatic, and we intend to study this compound further.” Ibogaine originally comes from a shrub native to Africa and has been used to treat depression, anxiety, addiction, PTSD, and brain trauma. However, medical experts stress that the drug carries real medical risks, including cardiac events and dangerous heart rhythm abnormalities.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://us.headtopics.com/news/trump-signs-executive-order-boosting-psychedelic-drug-82392474